Aurinia Pharmaceuticals Inc.
AUPH
$12.27
$0.191.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 260.11M | 247.30M | 235.13M | 220.36M | 207.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 260.11M | 247.30M | 235.13M | 220.36M | 207.11M |
| Cost of Revenue | 51.61M | 50.05M | 49.03M | 51.00M | 62.29M |
| Gross Profit | 208.51M | 197.25M | 186.10M | 169.36M | 144.82M |
| SG&A Expenses | 125.76M | 144.67M | 172.03M | 185.07M | 190.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 19.64M | 10.11M | 1.55M | 3.33M | 1.40M |
| Total Operating Expenses | 197.00M | 204.83M | 222.61M | 239.40M | 254.15M |
| Operating Income | 63.11M | 42.47M | 12.52M | -19.04M | -47.05M |
| Income Before Tax | 62.49M | 41.81M | 7.45M | -20.14M | -48.10M |
| Income Tax Expenses | 1.85M | 1.96M | 1.70M | 2.41M | 2.25M |
| Earnings from Continuing Operations | 60.64 | 39.85 | 5.75 | -22.55 | -50.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.64M | 39.85M | 5.75M | -22.55M | -50.35M |
| EBIT | 63.11M | 42.47M | 12.52M | -19.04M | -47.05M |
| EBITDA | 82.58M | 61.92M | 31.96M | 495.00K | -27.15M |
| EPS Basic | 0.44 | 0.28 | 0.04 | -0.16 | -0.35 |
| Normalized Basic EPS | 0.36 | 0.26 | 0.13 | -0.05 | -0.18 |
| EPS Diluted | 0.43 | 0.28 | 0.04 | -0.16 | -0.35 |
| Normalized Diluted EPS | 0.35 | 0.26 | 0.13 | -0.06 | -0.18 |
| Average Basic Shares Outstanding | 559.02M | 567.47M | 572.57M | 573.32M | 573.11M |
| Average Diluted Shares Outstanding | 574.05M | 580.64M | 581.45M | 576.70M | 573.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |